SEC Info - Revance Therapeutics, Inc. - ‘10-Q’ for 9/30/15

Revance Therapeutics, Inc. – ‘10-Q’ for 9/30/15 – ‘R1’

On: Tuesday, 11/10/15, at 5:11pm ET · For: 9/30/15 · Accession #: 1479290-15-10 · File #: 1-36297

Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 644K 2: EX-10.1 Material Contract HTML 28K 3: EX-10.2 Material Contract HTML 68K 4: EX-10.3 Material Contract HTML 64K 5: EX-10.4 Material Contract HTML 70K 6: EX-10.5 Material Contract HTML 68K 7: EX-10.6 Material Contract HTML 70K 8: EX-31.1 Certification -- §302 - SOA'02 HTML 27K 9: EX-31.2 Certification -- §302 - SOA'02 HTML 27K 10: EX-32.1 Certification -- §906 - SOA'02 HTML 23K 11: EX-32.2 Certification -- §906 - SOA'02 HTML 23K 45: R1 Document and Entity Information HTML 39K 35: R2 Condensed Consolidated Balance Sheets HTML 99K 43: R3 Condensed Consolidated Balance Sheets HTML 31K (Parenthetical) 48: R4 Condensed Consolidated Statement of Operations and HTML 92K Comprehensive Loss 61: R5 Consolidated Statements of Cash Flows HTML 171K 37: R6 The Company and Basis of Presentation HTML 36K 42: R7 Summary of Significant Accounting Policies HTML 39K 32: R8 Medicis Settlement HTML 30K 25: R9 Cash Equivalents and Investments HTML 82K 62: R10 Fair Value Measurements HTML 82K 50: R11 Notes Payable and Financing Obligation HTML 41K 49: R12 Convertible Notes, Warrants, and Related HTML 26K Derivatives 54: R13 Interest Expense HTML 62K 55: R14 Commitments and Contingencies HTML 40K 53: R15 Warrants HTML 22K 56: R16 Equity HTML 105K 44: R17 Net Loss per Share Attributable to Common HTML 62K Stockholders 46: R18 Subsequent Events HTML 25K 52: R19 Summary of Significant Accounting Policies HTML 52K (Policies) 66: R20 Cash Equivalents and Investments (Tables) HTML 78K 58: R21 Fair Value Measurements (Tables) HTML 79K 39: R22 Notes Payable and Financing Obligation (Tables) HTML 27K 51: R23 Interest Expense (Tables) HTML 60K 41: R24 Commitments and Contingencies (Tables) HTML 28K 22: R25 Equity (Tables) HTML 92K 59: R26 Net Loss per Share Attributable to Common HTML 62K Stockholders (Tables) 63: R27 The Company and Basis of Presentation - Additional HTML 60K Information (Detail) 28: R28 Medicis Settlement - Additional Information HTML 49K (Detail) 27: R29 Cash Equivalents and Investments (Details) HTML 44K 30: R30 Fair Value Measurements - Schedule of Fair Value HTML 53K of Financial Instruments (Detail) 31: R31 Fair Value Measurements - Summary of Changes in HTML 27K Fair Value of Financial Instruments (Detail) 33: R32 Notes Payable and Financing Obligation - Hercules HTML 54K Notes Payable (Detail) 21: R33 Notes Payable and Financing Obligation - Essex HTML 58K Capital Notes (Detail) 57: R34 Notes Payable and Financing Obligation - Summary HTML 29K of Aggregate Total Future Minimum Lease Payments under the Financing Obligation (Detail) 38: R35 Convertible Notes, Warrants, and Related HTML 61K Derivatives - Additional Information (Detail) 40: R36 Interest Expense - Summary of Interest Expense by HTML 42K Cash and Non-Cash Components (Detail) 24: R37 Commitments and Contingencies - Additional HTML 34K Information (Detail) 65: R38 Commitments and Contingencies - Schedule of Future HTML 38K Minimum Lease Payments under Non-Cancelable Operating Leases (Detail) 18: R39 Warrants - Additional Information (Detail) HTML 28K 34: R40 Equity - Additional Information (Detail) HTML 69K 60: R41 Equity - Fair Value Assumptions (Details) HTML 44K 23: R42 Equity - Schedule of Stock-based Compensation HTML 30K Expense (Details) 26: R43 Equity - Schedule of Accumulated Other HTML 33K Comprehensive Income (Details) 29: R44 Net Loss per Share Attributable to Common HTML 45K Stockholders - Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail) 36: R45 Net Loss per Share Attributable to Common HTML 34K Stockholders - Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share (Detail) 20: R46 Subsequent Events (Details) HTML 46K 64: XML IDEA XML File -- Filing Summary XML 106K 19: EXCEL IDEA Workbook of Financial Reports XLSX 58K 12: EX-101.INS XBRL Instance -- rvnc-20150930 XML 1.30M 14: EX-101.CAL XBRL Calculations -- rvnc-20150930_cal XML 173K 15: EX-101.DEF XBRL Definitions -- rvnc-20150930_def XML 354K 16: EX-101.LAB XBRL Labels -- rvnc-20150930_lab XML 1.10M 17: EX-101.PRE XBRL Presentations -- rvnc-20150930_pre XML 636K 13: EX-101.SCH XBRL Schema -- rvnc-20150930 XSD 123K 47: ZIP XBRL Zipped Folder -- 0001479290-15-000010-xbrl Zip 149K